As of 14 Oct 2026, Glycomine has raised $115M across 1 verified round on record; latest: $115 million Series C led by abrdn, Advent Life Sciences and 1 other, announced 16 Apr 2025.
Glycomine develops replacement therapies for rare genetic diseases, particularly focusing on PMM2-CDG treatments.
glycomine.comLinkedInSan Carlos, California
2 sources
Business Wire displays a May 14 publication date, but its dateline is Apr 16; the company's release fixes the announcement date as April 16, 2025.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series C [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $115M | 2025-04-16 | abrdn, Advent Life Sciences, CTI Life Sciences Fund | No recent discussion |
2 sources [ VERIFIED · CORRECTED ] read against 2 sources
Business Wire displays a May 14 publication date, but its dateline is Apr 16; the company's release fixes the announcement date as April 16, 2025. | ||||